Several state agencies, including the New York State Department of Health, have identified clinical assessment as a key facilitator of safe opioid prescribing.12 Evaluating patients on an ongoing basis provides the opportunity to determine treatment efficacy and adjust doses and agents. Additionally, a risk assessment can be performed and an intervention staged if indices of misuse are detected (Figure 2).13 Our institutional guidelines require the patient to be physically present when the initial prescription for a controlled substance is made. No new prescriptions are made or refilled if the patient has not been seen and examined within the prior 30 days (New York State Law allows an initial 7-day supply of controlled substances, with a 30-day refill or renewal for the same condition). These circumstances are documented in the electronic medical record, along with a pain diagnosis, indication for opioid use, and details of the regimen, strength, and directions for use and tapering.
Combating opioid abuse has become a top priority at the state and federal levels. The US Department of Health and Human Services has articulated an approach to combat opioid abuse, which emphasizes health care information technology to prevent prescription misuse, promoting safer treatment of pain conditions and a timeline with targeted interventions for minimizing abuse and misuse.14 The states have also recognized the opioid crisis: Legislation authorizing the creation and use of a Prescription Drug Monitoring Program (PDMP) has been enacted in all states (except Missouri), the District of Columbia, and Territory of Guam. PDMPs collect electronic data regarding controlled substance prescriptions from in-state pharmacies and mail-order pharmacies that ship prescriptions into the state. Accessing the state PDMP allows prescribers to obtain their patients’ controlled substance prescription history, including dose, supplier, and frequency of refill.
PDMPs are a valuable resource to identify patients who may be engaged in high-risk behavior, or who are at risk for abuse of or dependence on controlled substances. For example, patients who routinely obtain controlled substances from multiple prescribers are 7 times more likely to die of opioid overdose than those who do not; patients who obtain medications from more than 1 pharmacy are over 13 times more likely to suffer an overdose death.15 Proponents argue that compulsory PDMP consultation is necessary and sufficient to change prescribing behavior and reduce opioid abuse.16 Indeed, Florida reported a decline in the number of “doctor shoppers” and prescription drug overdose deaths after implementation of PDMPs.17 Critics point to other data suggesting small, mixed effects of PDMPs on influencing prescribing practices, poor study design, and low prescriber utilization of PDMPs.18,19
Academic arguments notwithstanding, our local guidelines were developed according to applicable state and federal laws (Figure 3). All HSS practitioners who prescribe, administer, or dispense controlled substances are registered with the US Drug Enforcement Administration and hold an active New York State License appropriate to their clinical certification. New York State has instituted mandatory electronic prescribing for all controlled substances, after compulsory review of the state PDMP. We further mandated that HSS prescribers are personally responsible for each prescription: Designating an assistant to generate or sign electronic prescriptions via shared passwords or access to e-prescribing is strictly prohibited. In contrast, review of the state PDMP may be delegated if an assistant is properly credentialed, but they must use their own username and password. The ultimate responsibility for reviewing the PDMP information rests with the prescriber.
The PDMP must be interrogated within 24 hours of any prescription for controlled substances. Once checked, the prescriber must document the query and any relevant findings, particularly concurrent use of other controlled substances or signs of prescription drug misuse (Figure 2).
To ensure compliance with applicable laws and regulations, our local Department of Internal Audit and Corporate Compliance performs continuous monitoring of controlled substance prescribing and of our written policies and guidelines. It is also made clear to all prescribers that failure to comply may result in disciplinary action. The written policies have been distributed to all clinicians, together with directions for reporting violations or concerns about clinical practices or applicable laws.
THE OPIOID-TOLERANT PATIENT PRESENTING FOR ELECTIVE ORTHOPEDIC SURGERY
Elective orthopedic surgery is frequently indicated to address a painful condition. Thus, the prevalence of opioid use at the time of surgery tends to be significantly higher in orthopedic patients compared to the general surgical population.20–23 The development of opioid tolerance leads to decreased analgesic effects over time, and consequently, dose escalation to achieve adequate pain control. Additionally, long-term opioid use can lead to opioid-induced hyperalgesia (OIH), an enhanced painful response to painful stimuli.24 Tolerance and OIH frequently co-occur, necessitating a careful approach to opioid management across the perioperative period. However, evidence guiding management is limited and principally comes from case reports, case series, and expert opinion.6,25,26 We have updated the evidence base for key components in management to create the HSS guidelines (the summary guidelines are provided in Figure 4).
Identify Opioid Tolerance
Preoperative opioid use and dependence are linked to longer hospital length of stay, poor functional recovery, and more complications after spine surgery,27 major elective orthopedic procedures,28 and hip,29 knee,30 and shoulder arthroplasty.31 According to the US Food and Drug Administration, opioid tolerance is defined in patients taking 60 mg oral morphine daily, or an equianalgesic dose of another opioid, for at least 1 week.32 The US Centers for Disease Control and Prevention definition of long-term opioid therapy is the use of opioids on most days for >3 months.3
Opioid tolerance should be diagnosed preoperatively. Early identification minimizes the risk of acute withdrawal, provides an opportunity to optimize preoperative status, and allows time to formulate a postoperative analgesic plan.26 Doses of prescribed controlled substances should be verified via the relevant state PDMP, or by contacting the original prescriber or dispensing pharmacist.
At HSS, we set the goal of identifying all opioid-tolerant patients before elective surgery. To identify this cohort, we instituted a simple tool called “Ask Every Patient” (Figure 5): a set of 5 questions to ask every patient during the preoperative evaluation phase. Positive answers necessitate further review to establish whether the patient has a SUD, complex pain condition, or opioid tolerance. These conditions in turn prompt a referral for a pain management evaluation (Figure 5). Opioid-tolerant patients presenting for elective surgery who have not been preidentified and optimized typically have their procedure postponed until this can be done. Referrals are also made for all patients with a history of SUD, irrespective of whether they are taking abstinence therapy (or the same agents indicated for chronic pain), or have an intrathecal analgesic pump.
Identify Any Concurrent SUD
It is imperative to diagnose SUD in patients with chronic pain because of the frequency with which the 2 conditions co-occur: The prevalence of substance abuse disorder is significantly higher in patients with chronic pain compared to the general population.33 Conversely, patients seeking treatment for addiction report more chronic pain and more severe pain.34 Each makes the other more difficult to treat.35 Although evidence to guide optimal management strategies is lacking, consensus guidelines recommend referral to an addiction specialist for all patients who meet criteria for SUD.36,37
Based on these data, our institutional practice is to ask every patient about their history of drug and alcohol use and misuse, including prescription drug abuse (Figure 5). We are currently transitioning to a practice of referring all patients with positive history of SUD to an addiction specialist for counseling and treatment before elective procedures. Patients who have been referred for a preoperative pain management consultation who have urine toxicology results consistent with SUD are likewise referred.
Patients on methadone maintenance for addiction should be identified and doses verified as for any controlled substance. These patients should typically continue their daily dose of methadone and receive a different opioid for acute pain. Buprenorphine should be stopped preoperatively, under the auspices of a pain management or addiction specialist, and short-acting opioids can be substituted for analgesia.38
The Preoperative Pain Consult
The main goals of the consultation are to clarify which patients might be at risk for opioid overdose, misuse disorder, OIH, or difficult-to-control pain, and to determine which patients will benefit from extended monitoring or interventions when risk factors are present. Optimization typically includes tapering opioids, or transitioning to nonopioid analgesics before surgery.
The nature and extent of a preoperative pain management evaluation depends on the patient and their pain history. A careful history is taken, focusing on the context in which the pain has occurred, the patient’s past and current treatments for pain, preferences for analgesics, and any underlying or co-occurring disorders and conditions.6 The nature of the planned procedure, the expected pain caused by that procedure, and the likely duration of that pain are clarified.
For every patient, the initial evaluation includes a review of systems and relevant physical examination, as well as laboratory investigations. At HSS, preoperative pain management consultations ideally occur a minimum of 2 weeks before surgery to allow for toxicity screen results to be returned before the surgery date. Urine drug screening is a useful tool to monitor patients on chronic opioid therapy, and may help identify patients with risk factors for drug abuse or diversion.39 Abnormal results—including the absence of prescribed opioids and presence of drugs of abuse or addiction—should prompt a review of underlying causes, including self-treatment of uncontrolled pain, psychological issues, or diversion.40 Assessment of the patient’s personal and family history of alcohol or drug abuse and relative risk for medication misuse or abuse is also part of the initial evaluation, and ideally completed before deciding whether to prescribe opioid analgesics.
During the preoperative assessment, plans for postdischarge care can be initiated. A key aspect to successful postoperative care is the involvement of the community pain management provider. The HSS pain management consultant identifies the outpatient prescriber early in the preoperative phase and establishes direct communication. In addition to confirming the preoperative home regimen, treatment plans are coordinated and arrangements to transition postoperative care and prescribing responsibility are made.
For patients deemed optimized for surgery, the surgeon reviews the pain management consultation note and provides acknowledgment that he or she has reviewed the note. On occasion, the pain management consultant deems the patient not optimized for surgery due to high opioid requirement, aberrant behavior, or other factors. If the recommendation is to postpone surgery for medical optimization or opioid tapering, surgery will not be scheduled until these tasks are completed. For a subset of highly complex patients, it may be necessary to convene a multidisciplinary group to decide whether the surgery should proceed at all, be postponed, and, if so, how to best prepare the patient.
Tapering Baseline Opioid Consumption
Traditionally, the surgical literature and pain consensus guidelines have not recommended routine preoperative opioid reduction. The rationale is that continuation of usual doses will minimize the risk of withdrawal or pain crisis immediately before surgery. However, there is evidence in the orthopedic literature that links preoperative opioid reduction with superior outcomes after surgery in opioid-tolerant patients.21,27–29,41 A tapering strategy may also help to limit OIH.24
Given these data, HSS pain management specialists supervise careful opioid dose reduction before elective procedures. Although the optimal tapering regimen (amount and duration) are unknown, evidence suggests weaning to 50% of baseline is associated with improved outcomes.41 Patients are instructed not to stop their opioid analgesics “cold turkey,” and not to attempt dose reductions without a plan made in conjunction with their pain management specialist.
Preventing Opioid Withdrawal
On the day of surgery, the history should include the date and time of last opioid administration. The baseline dose of home opioid should be taken at the regular time; however, patients often omit their daily dose(s) because of confusion regarding preoperative fasting requirements.42 Approximately 50% of the baseline dose is required to prevent withdrawal symptoms.42,43 If the patient has omitted the expected dose, this should be provided before the procedure.
Maximizing Opioid Alternatives: Multimodal Analgesia
The concept of multimodal analgesia refers to the use of 2 or more analgesic interventions with different mechanisms of action. Multimodal analgesia was first proposed in the early 1990s with dual goals of providing analgesia and minimizing opioid-induced adverse effects.44,45 High-quality evidence to support the routine use of component therapies is abundant, and covers both pharmacologic- and nonpharmacologic-based tools. A complete review is beyond the scope of the current article, but typical agents include acetaminophen, nonsteroidal anti-inflammatories, ketamine, regional anesthetic techniques (peripheral nerve blocks and epidural catheters), and cryotherapy.5 The opportunities to use nonopioid analgesics are plentiful, since they can be used preoperatively (as part of a preemptive/preventive regimen), intraoperatively (to block surgical nociception), and postoperatively (the major role for multimodal strategies).
The benefits of multimodal analgesia are compelling, particularly regarding the opioid-sparing effect. Recommendations from multiple pain and anesthetic societies repeatedly endorse the use of multimodal analgesia wherever possible.4,5,46 Contrary to these recommendations, data suggest that multimodal analgesia has yet to be widely incorporated into clinical practice. Emerging data describing trends on adoption suggest multimodal therapy is used in just 25%–50% of surgical patients.47,48 National studies on the use of regional anesthesia and analgesia indicate similar low rates of uptake, with approximately 20% of joint arthroplasty patients receiving neuraxial and peripheral nerve blocks.49
Postoperative Transition of Care
According to recent data, patients on chronic opioid therapy before surgery may be discharged on up to 3 times their baseline dose of opioid, with little or no accompanying advice for weaning.50 Primary (community) pain medication prescribers may be placed in a difficult position caring for patients on new, higher doses of opioids after surgery. It has long been recognized that there is a gap between supervised in-hospital pain management and ongoing care in the community.
There are limited data regarding how best to manage this key transition in care. However, multidisciplinary, collaborative approaches are being described in the literature. In these models, 1 hospital-clinician oversees pain management decisions, but teams encompass expertise from anesthesiology, nursing, pharmacy, and social work. The goals are to manage postsurgical and chronic pain, optimize the analgesic regimen while minimizing opioids, and provide education and liaison between the hospital and community.51,52
Education initiatives have been repeatedly demonstrated to change patient behaviors, empower patients to actively participate in their own care, and improve clinical outcomes in a host of medical and surgical conditions.53 In last year’s guidelines for opioid prescribing, the Centers for Disease Control and Prevention called for clinicians to educate patients regarding the risks of opioid therapy when initiating treatment.3 Recommended topics included the dangers of sharing medications, risk of long-term dependence or addiction, and methods for safe storage and disposal. The authors noted that, at the time of writing, there was no evidence to evaluate the effectiveness of patient-education or risk-mitigation strategies for prescription opioids. Few reports have been published in the interim, but data thus far suggest that providing structured education to patients is associated with lower rates of patient-reported “pill saving,”54 opioid sharing, and unsafe storage, as well as improved knowledge of the risks of opioid misuse.55
An allied opportunity to educate patients can be created during the preoperative period. At the time, expectations for pain after surgery and boundaries for appropriate opioid prescribing can be set. The importance of patient reassurance and expectation setting is highlighted by a report in which preoperative counseling was provided to an orthopedic trauma cohort.20 Structured sessions including advice and information regarding the role of opioids in recovery were associated with lower rates of opioid use at 6 weeks postsurgery.
More evidence is clearly needed to support the use of educational interventions and to identify best practices for implementation. The main drawbacks of patient-education programs are that provision is resource-intense and currently requires the use of incompletely validated methods and content. However, we decided that these disadvantages were outweighed by the potential benefits for safety and patient satisfaction. Thus, we incorporated new content into existing preoperative patient-education classes, across service lines. All patients who attend a preoperative class now receive education about expected pain burden, multimodal analgesia, and appropriate opioid use and risks. Of course, attendance at the classes determines whether patients receive this information. A nurse will discuss the material with any patient who does not attend the class, and document the discussion in the electronic medical record. To reinforce the information, patients are provided with a Prescription Drug Fact Sheet for Surgical Patients at discharge (Figure 6). The Fact Sheet outlines how to safely use, store, and dispose of controlled substances; describes the risks associated with misusing controlled substances; and provides links to further resources, sources of information, and advice.
Most physicians receive little or no training during medical school regarding evidence-based opioid prescribing, SUDs and pain management, and only 5 states require continuing medical education (CME) on these topics.56 Up-to-date CME programs that present the evidence for safe opioid prescribing may help reduce associated morbidity and mortality. Educational interventions have demonstrated effectiveness for changing prescribing habits, particularly those which use a structured method for choosing and monitoring medications.57
To address potential deficiencies in background and training, we have developed a mandatory education program for all HSS prescribers. Although the program incorporates the learning objectives mandated by New York State, the content has been customized to reflect our own specialized practice caring for orthopedic surgery patients. The program comprises a combination of classroom (lecture)-based and online (self-directed) modules. Topics covered include: (1) a review of evidence-based best practices for pain management, addiction, and palliative care, with emphasis on patient risk assessments and documentation; (2) training in safe and competent use of opioids; and (3) instruction on state and federal requirements for prescribing controlled substances. The course has been certified for CME accreditation. The materials are stored in an online, accessible format so they remain available for review at any time after completion of the course. Formal re-education and recertification will be undertaken every 3 years (in accordance with New York State Department of Health requirements). All HSS prescribers attest to completing this required training through the New York State Department of Health Commerce System.
A key question for practices considering an opioid management program is the cost. Referrals to pain management, routine urine testing, and administrative support for education and compliance are undeniably expensive. Depending on the size and type of practice setting, individual cost impact analyses may be required to determine the scope and components of an opioid management program. However, several general financial arguments can be made that the short-term costs of an opioid management program are offset by longer-term savings. First, multifaceted, multidisciplinary programs have been successfully used to achieve cost and clinical savings in many other chronic diseases. For example, interventions that optimize diabetes mellitus are associated with reductions in length of hospital stay, fewer complications, and cost savings.58 Second, opioid users consistently have higher costs per hospital admission, longer length of stay, more complications, and more readmissions after surgery.59–61 These data suggest that interventions targeting the opioid-tolerant patient may represent a useful tool to improve the value of surgical care. Third, as care and outcomes are improved, the capacity to increase surgical volume may help to offset the cost of opioid implementation programs. When developing our program, we used these arguments to advocate for resources from the hospital administration to support implementation.
OUTCOMES AND RESEARCH
The approach to opioid management described here has only recently been put into place at HSS. Thus far, few data exist regarding the effectiveness of these measures. A full evaluation of efficacy is currently hampered by 3 main factors: (1) we are unable to ensure that all measures have been systematically implemented (for example, we lack a mechanism to evaluate whether all opioid-tolerant patients are detected and optimized before surgery); (2) the program is too recent to demonstrate trends toward improved clinical and financial outcomes; and (3) as described above, some components have not been individually studied for their effectiveness in improving outcomes and minimizing opioid use. All 3 represent areas of ongoing evaluation at our institution. To determine whether the program has a positive effect on the problem, data regarding length of hospital stay, complication and readmission rates after surgery, quantitative measurement of opioid prescribing, and physician and patient attitudes before and after implementation of the program need to be evaluated.
As the current article highlights, there are few studies exploring perioperative pain and analgesia in the opioid-tolerant patient. Pro- and retrospective studies that determine the average pain burden after surgery compared to the amount and duration of opioid prescribed are needed in this population. Likewise, data regarding the optimal analgesic technique are lacking in the opioid-tolerant patient; for example, how opioid-tolerant patients may benefit from peripheral nerve catheter techniques or blocks with adjuvants to extend duration. Finally, it is unknown how preoperative opioid use contributes to poor postsurgical outcomes and whether opioid use is a marker of more severe or different underlying pathology.
Opioids are essential for effective analgesia after most orthopedic procedures. However, prescribing disproportionate doses and quantities of opioids for perioperative pain will only perpetuate the epidemic. Despite significant advances toward understanding the dangers of opioids, rates of addiction, overdose, and death continue to rise. Coordinated efforts by patients, physicians, administrators, and legislators are essential to combat the crisis—and are starting to be proposed. The HSS program described here focuses on integrating evidence-based data (where they exist), with best practice into an opioid management model that also conforms to applicable laws and regulations. The efforts described here focus on the supply side of the prescription abuse crisis. Of course, halting the epidemic is not as simple as controlling a single contributor. Reducing access is clearly important, but efforts to reduce demand, understand and treat addiction, and ensure the humane treatment of acute and chronic pain are essential components too. Ultimately, we intend that the initiatives described here will contribute to a balance between effective analgesia for patients, while limiting the availability of opioids in the community.
Generalizability of the HSS Opioid Management Program
Orthopedic surgery plays a prominent role in the opioid prescription epidemic, and the authors practice at a specialty orthopedic hospital. Thus, the development of our opioid management program is likely to influence local clinical and social outcomes. However, the interventions described here may not apply universally to other practice settings, particularly nonacademic centers, those without an electronic medical record, locales that do not participate in PDMPs, and where surgery is less often indicated for painful conditions, or causes less pain. Additionally, we care for a predominately urban patient population, so some components may not be generalizable to rural or suburban settings. However, we advocate that similar interventions could be adapted as appropriate by considering the local patient population, prescribing habits, and available resources.
The authors gratefully acknowledge the support and leadership of Lou Shapiro, MHA, President & CEO and the contributions of the HSS Controlled Substances Task Force to the creation and development of the initiatives described in this manuscript. In particular: Peter Grimaldi, PA-C, MS, MPT, MBA, Senior Director, Physician Assistant Department; Christine Peterson, MD, Director, Inpatient Pain Medicine Services; Joanne Melia, Assistant Vice President, Risk Management; and Susan Cardamone, MBA, Director, Department of Anesthesiology.
Name: Ellen M. Soffin, MD, PhD.
Contribution: This author helped extensively to this study. This author helped research and write the main drafts of the manuscript; discussed, revised, and edited the final version; and approved the final version for publication.
Conflicts of Interest: None.
Name: Seth A. Waldman, MD.
Contribution: This author helped extensively to this study; discussed, revised, and edited the final version; and approved the final version for publication.
Conflicts of Interest: Seth A. Waldman is the Chair of the Hospital for Special Surgery Controlled Substances Task Force. Seth A. Waldman led Hospital for Special Surgery’s response to the opioid epidemic, and developed much of the content described herein.
Name: Roberta J. Stack, MS.
Contribution: This author helped extensively to this study; discussed, revised, and edited the final version; and approved the final version for publication.
Conflicts of Interest: Roberta J. Stack is the Co-Chair of the Hospital for Special Surgery Controlled Substances Task Force. Roberta J. Stack led Hospital for Special Surgery’s response to the opioid epidemic, and developed much of the content described herein.
Name: Gregory A. Liguori, MD.
Contribution: This author helped extensively to this study; discussed, revised, and edited the final version; and approved the final version for publication.
Conflicts of Interest: Gregory A. Liguori led Hospital for Special Surgery’s response to the opioid epidemic, and developed much of the content described herein.
This manuscript was handled by: Honorio T. Benzon, MD.
1. Morris BJ, Mir HR. The opioid epidemic: impact on orthopaedic surgery. J Am Acad Orthop Surg. 2015;23:267–271.
2. Levin P. Comment on: the opioid epidemic: impact on orthopaedic surgery. J Am Acad Orthop Surg. 2015; 23:e36–e37.
3. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1–49.
4. American Society of Anesthesiologists Task Force on Acute Pain ManagementPractice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116:248–273.
5. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17:131–157.
7. Rodgers J, Cunningham K, Fitzgerald K, Finnerty E. Opioid consumption following outpatient upper extremity surgery. J Hand Surg Am. 2012;37:645–650.
8. Kim N, Matzon JL, Abboudi J, et al. A prospective evaluation of opioid utilization after upper-extremitysurgical procedures: identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am. 2016;98:e89.
9. Kumar K, Gulotta LV, Dines JS, et al. Unused opioid pills after outpatient shoulder surgeries given current perioperative prescribing habits. Am J Sports Med. 2017;45:636–641.
10. Bicket M, White E, Wu C, et al. Prescription opioid oversupply following orthopedic surgery: a prospective cohort study. J Pain. 2017;18:S34.
11. Stanek JJ, Renslow MA, Kalliainen LK. The effect of an educational program on opioid prescription patterns in hand surgery: a quality improvement program. J Hand Surg Am. 2015;40:341–346.
13. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician. 2006;52:1081–1087.
15. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.
17. Johnson H, Paulozzi L, Porucznik C, et al. Decline in drug overdose deaths after state policy changes – Florida, 2010–2012. Morbid Mortal Wkly Rep. 2014;63:569–574.
18. Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff. 2015;34:484–492.
19. Haffajee RL, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. JAMA. 2015;313:891–892.
20. Holman JE, Stoddard GJ, Horwitz DS, Higgins TF. The effect of preoperative counseling on duration of postoperative opiate use in orthopaedic trauma surgery: a surgeon-based comparative cohort study. J Orthop Trauma. 2014;28:502–506.
21. Armaghani SJ, Lee DS, Bible JE, et al. Preoperative opioid use and its association with perioperative opioid demand and postoperative opioid independence in patients undergoing spine surgery. Spine. 2014;39:E1524–E1530.
22. Wilson JL, Poulin PA, Sikorski R, Nathan HJ, Taljaard M, Smyth C. Opioid use among same-day surgery patients: prevalence, management and outcomes. Pain Res Manag. 2015;20:300–304.
23. Zarling BJ, Yokhana SS, Herzog DT, Markel DC. Preoperative and postoperative opiate use by the arthroplasty patient. J Arthroplasty. 2016;31:2081–2084.
24. Weber L, Yeomans DC, Tzabazis A. Opioid-induced hyperalgesia in clinical anesthesia practice: what has remained from theoretical concepts and experimental studies? Curr Opin Anaesthesiol. 2017;30458–465.
25. Mahathanaruk M, Hitt J, de LeonCasasola OA. Perioperative management of the opioid tolerant patient for orthopedic surgery. Anesthesiol Clin. 2014;32:923–932.
26. Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care. 2011;39:804–823.
27. Lee D, Armaghani S, Archer KR, et al. Preoperative opioid use as a predictor of adverse postoperative self-reported outcomes in patients undergoing spine surgery. J Bone Joint Surg Am. 2014;89:1–8.
28. Menendez ME, Ring D, Bateman BT. Preoperative opioid misuse is associated with increased morbidity and mortality after elective orthopaedic surgery. Clin Orthop Relat Res. 2015;473:2402–2412.
29. Pivec R, Issa K, Naziri Q, Kapadia BH, Bonutti PM, Mont MA. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop. 2014;38:1159–1165.
30. Zywiel MG, Stroh DA, Lee SY, Bonutti PM, Mont MA. Chronic opioid use prior to total knee arthroplasty. J Bone Joint Surg Am. 2011;93:1988–1993.
31. Morris BJ, Sciascia AD, Jacobs CA, Edwards TB. Preoperative opioid use associated with worse outcomes after anatomic shoulder arthroplasty. J Shoulder Elbow Surg. 2016;25:619–623.
33. Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain. 2011;152:488–497.
34. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289:2370–2378.
35. Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4:4–25.
36. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.
37. Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125:115–130.
38. Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine. Anesthesiology. 2017;126:1180–1186.
39. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18:S76–S82.
40. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27:260–267.
41. Nguyen LC, Sing DC, Bozic KJ. Preoperative reduction of opioid use before total joint arthroplasty. J Arthroplasty. 2016;31:282–287.
42. Carroll IR, Angst MS, Clark JD. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med. 2004;29:576–591.
43. Lewis NL, Williams JE. Acute pain management in patients receiving opioids for chronic and cancer pain. BJA Education. 2005;5:127–129. Available at: https://doi.org/10.1093/bjaceaccp/mki034
. Accessed July 16, 2017.
44. Dahl JB, Rosenberg J, Dirkes WE, Mogensen T, Kehlet H. Prevention of postoperative pain by balanced analgesia. Br J Anaesth. 1990;64:518–520.
45. Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg. 1993;77:1048–1056.
46. Gordon DB, Dahl JL, Miaskowski C, et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165:1574–1580.
47. Baratta JL, Gandhi K, Viscusi E. Patterns of multimodal utilization in the United States. Paper presented at: American Society of Anesthesiologists 2011 Annual Meeting: Abstract 1178; October 18, 2011; Chicago, IL.
48. Ladha KS, Patorno E, Huybrechts KF, Liu J, Rathmell JP, Bateman BT. Variations in the use of perioperative multimodal analgesic therapy. Anesthesiology. 2016;124:837–845.
49. Cozowicz C, Poeran J, Zubizarreta N, Mazumdar M, Memtsoudis SG. Trends in the use of regional anesthesia: neuraxial and peripheral nerve blocks. Reg Anesth Pain Med. 2016;41:43–49.
50. Clarke H. Transitional Pain Medicine: novel pharmacological treatments for the management of moderate to severe postsurgical pain. Expert Rev Clin Pharmacol. 2016;9:345–349.
51. Katz J, Weinrib A, Fashler SR, et al. The Toronto General Hospital Transitional Pain Service: development and implementation of a multidisciplinary program to prevent chronic postsurgical pain. J Pain Res. 2015;8:695–702.
52. Philips BD, Liu SS, Wukovits B, et al. Creation of a novel recuperative pain medicine service to optimize postoperative analgesia and enhance patient satisfaction. HSS J. 2010;6:61–65.
53. Greene J, Hibbard JH, Alvarez C, Overton V. Supporting patient behavior change: approaches used by primary care clinicians whose patients have an increase in activation levels. Ann Fam Med. 2016;14:148–154.
54. Hero JO, McMurtry C, Benson J, Blendon R. Discussing opioid risks with patients to reduce misuse and abuse: evidence from 2 surveys. Ann Fam Med. 2016;14:575–577.
55. de la Cruz M, Reddy A, Balankari V, et al. The impact of an educational program on patient practices for safe use, storage, and disposal of opioids at a comprehensive cancer center. Oncologist2017;22:115–121.
56. Davis CS, Carr D. Physician continuing education to reduce opioid misuse, abuse, and overdose: many opportunities, few requirements. Drug Alcohol Depend. 2016;163:100–107.
57. Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve prescribing competency: a systematic review. BMJ Open. 2013;3:e003291.
58. Sudhakaran S, Surani SR. Guidelines for perioperative management of the diabetic patient. Surg Res Pract. 2015;2015:284063.
59. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–667.
60. Cron DC, Englesbe MJ, Bolton CJ, et al. Preoperative opioid use is independently associated with increased costs and worse outcomes after major abdominal surgery. Ann Surg. 2017;265:695–701.
© 2017 International Anesthesia Research Society
61. Waljee JF, Cron DC, Steiger RM, Zhong L, Englesbe MJ, Brummett CM. Effect of preoperative opioid exposure on healthcare utilization and expenditures following elective abdominal surgery. Ann Surg. 2017;265:715–721.